Table 1.
OAC Treatment of AF Detected Before the Study Versus During the Study
| Patients With AF (Aged ≥65 y) | Class 1 OAC Recommendation Group | CHA2DS2‐VASc, Mean | Age, Mean, y | Male Sex, % | ||||
|---|---|---|---|---|---|---|---|---|
| Total, No. | Class 1 OAC Recommendation, No. (%)* | Prescribed OAC, No. (%) | Prescribed Antiplatelet Only, No. (%) | No Therapy, No. (%) | ||||
| AF diagnosed before study | 1346 | 1306 (97) | 933 (71)† | 213 (16) | 160 (12) | 3.9 | 80.0 | 53 |
| AF diagnosed during study | 66 | 64 (97) | 54 (85)† | 3 (5) | 7 (11) | 3.8 | ||
| Screen‐detected AF | 19 | 18 (95) | 15 (83) | 1 (6) | 2 (11) | 3.8 | 78.6 | 53 |
| Otherwise‐detected AF | 47 | 46 (98) | 39 (85) | 2 (4) | 5 (11) | 3.8 | 79.6 | 45 |
AF indicates atrial fibrillation; CHA2DS2‐VASc: C, congestive heart failure/left ventricular dysfunction; H, high blood pressure; A2, age older than 75 years; D, diabetes mellitus; S2, stroke/transient ischemic attack/thromboembolism; V, vascular disease (coronary artery disease, myocardial infarction, peripheral artery disease, aortic plaque); A, age 65 to 74 years; Sc, sex category female.
*
Oral anticoagulant (OAC) recommendations as per European Society of Cardiology 2016 guidelines.12
†
Between‐group difference (P<0.001).